Roche Holdings Ltd ADR (RHHBY)

$40.02 -0.29 (-0.72%)
Market Cap 258.94B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.36
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 897,257
Avg Vol 1,289,634
Day's Range N/A - N/A
Shares Out 6.38B
Stochastic %K 27%
Beta 0.45
Analysts Sell
Price Target $44.62

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
jabber621
jabber621 Jul. 30 at 4:32 PM
$RHHBY It looks like they have some block buster drugs in the pipeline. Can someone tell me why it is not being reflected in the stock price?
0 · Reply
Quantumup
Quantumup Jul. 30 at 2:52 PM
Raymond James assumed $SRRK Strong Buy⬆️PT=$53 was $49 &said "While expectations are elevated ahead of apitegromab approval this fall, we are confident in the value proposition of apitegromab in SMA, with plenty of long-term optionality in the pipeline." $RHHBY $BIIB $NVS $BHVN Raymond James: $SRRK's apitegromab, a mAb targeting latent myostatin, is progressing towards a Sept. 22 PDUFA date in spinal muscular atrophy (SMA), and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner—beyond SMA, $SRRK's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential out-licensing and partnerships in the obesity space can offer another source of near-term optionality.
0 · Reply
DatNegusTrav
DatNegusTrav Jul. 30 at 8:55 AM
$LMDX $RHHBY https://finance.yahoo.com/news/rapid-expansion-innovation-drive-36-174300653.html
2 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 10:33 PM
$LMDX $FCN $RHHBY $NDAQ Happy 1 year anniversary $RHHBY from robbing $LMDX Shareholders! Our Time will Come! The most recent formal statement from Roche concerning LumiraDx appears in its July 29, 2024 media release announcing the completion of the acquisition of LumiraDx’s point‑of‑care technology. In that statement, Matt Sause, CEO of Roche Diagnostics, said: “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.”  From LumiraDx—with the CEO, Veronique Ameye, stating: “We are absolutely delighted to continue our journey as part of Roche Diagnostics … Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community‑based healthcare around the world.”
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 4:04 AM
$FCN $LMDX $NDAQ $RHHBY 🚨 LMDX Shareholders We Got Screwed 🚨 LumiraDx was not a normal bankruptcy. • $295M went to pay off insiders & secured lenders • Shareholders got ZERO • Then Zwanziger, Scott & McAleer quietly launched ElectraDx — same business, new name, no debt • Veronique Ameye dismantled the company… then took a role with Roche • The Gates-funded TB test? Gone. Patents continued after liquidation. Value never disclosed. This was a coordinated asset grab and shareholders were out of sight and mind throughout the whole process. Don’t let them erase us. Don’t let them walk with the tech that we helped invest in while we’re left holding the bag. #LMDX #LumiraDx #Roche #ElectraDx #ShareholderJustice #Fraud
1 · Reply
qwertylicious2003
qwertylicious2003 Jul. 28 at 3:16 PM
$RHHBY Trontinemab phase 3 announced shortly after closing ph2 enrollment. Very nice to see Roche move fast on progressing programs for early AD. $LCTX See guys - even though Trontinemab ph2 completion date shows 2031, its clear to see we could see ph2 close out enrollment and have a subsequent pivotal announcement very soon. With pivotal announcement comes $$$ in milestones and warrants. Big question is - do we get acquired prior to? Only time will tell!
3 · Reply
mrsBull
mrsBull Jul. 28 at 9:50 AM
$LMDX $RHHBY yes, yes, yes, yes and yes. I haven’t visited Lumira’s board for months now but I stand by my early opinion that the only chance shareholders had to see any kind of money was a lawsuit citing breach of duty. Lost a lot of money here, gain a valuable lesson (like with our friendly Chinese scam $MLGO ) Unless there’s a class action planned it’s time to move on guys
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 28 at 3:20 AM
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms $RHHBY https://stocktwits.com/news/equity/markets/roche-bets-big-on-alzheimer-s-prevention-with-new-trial-as-duchenne-drug-setback-looms/choeBswR5DR
0 · Reply
DonCorleone77
DonCorleone77 Jul. 28 at 3:02 AM
$RHHBY From Bloomberg: "Roche to Test Whether New Drug Can Prevent Alzheimer’s Disease" https://www.bloomberg.com/news/articles/2025-07-27/roche-to-test-whether-new-drug-can-prevent-alzheimer-s-disease?sref&
0 · Reply
Bulltrader988
Bulltrader988 Jul. 27 at 8:14 PM
$TPST there is a possible explanation for the run up last week and these rumours... $RHHBY so Roche failed in their product TIGIT https://www.oncologypipeline.com/apexonco/5000-patients-later-roche-scraps-its-tigit $TPST has possible solution.... $TPST 🤝🤝 $RHHBY already had a partnership together 👃👀
2 · Reply
Latest News on RHHBY
No data available.
jabber621
jabber621 Jul. 30 at 4:32 PM
$RHHBY It looks like they have some block buster drugs in the pipeline. Can someone tell me why it is not being reflected in the stock price?
0 · Reply
Quantumup
Quantumup Jul. 30 at 2:52 PM
Raymond James assumed $SRRK Strong Buy⬆️PT=$53 was $49 &said "While expectations are elevated ahead of apitegromab approval this fall, we are confident in the value proposition of apitegromab in SMA, with plenty of long-term optionality in the pipeline." $RHHBY $BIIB $NVS $BHVN Raymond James: $SRRK's apitegromab, a mAb targeting latent myostatin, is progressing towards a Sept. 22 PDUFA date in spinal muscular atrophy (SMA), and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner—beyond SMA, $SRRK's myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential out-licensing and partnerships in the obesity space can offer another source of near-term optionality.
0 · Reply
DatNegusTrav
DatNegusTrav Jul. 30 at 8:55 AM
$LMDX $RHHBY https://finance.yahoo.com/news/rapid-expansion-innovation-drive-36-174300653.html
2 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 10:33 PM
$LMDX $FCN $RHHBY $NDAQ Happy 1 year anniversary $RHHBY from robbing $LMDX Shareholders! Our Time will Come! The most recent formal statement from Roche concerning LumiraDx appears in its July 29, 2024 media release announcing the completion of the acquisition of LumiraDx’s point‑of‑care technology. In that statement, Matt Sause, CEO of Roche Diagnostics, said: “Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries.”  From LumiraDx—with the CEO, Veronique Ameye, stating: “We are absolutely delighted to continue our journey as part of Roche Diagnostics … Being an integral part of the Roche network opens the door to realising the full potential of our Point of Care technology, and to increasing patient access to community‑based healthcare around the world.”
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 29 at 4:04 AM
$FCN $LMDX $NDAQ $RHHBY 🚨 LMDX Shareholders We Got Screwed 🚨 LumiraDx was not a normal bankruptcy. • $295M went to pay off insiders & secured lenders • Shareholders got ZERO • Then Zwanziger, Scott & McAleer quietly launched ElectraDx — same business, new name, no debt • Veronique Ameye dismantled the company… then took a role with Roche • The Gates-funded TB test? Gone. Patents continued after liquidation. Value never disclosed. This was a coordinated asset grab and shareholders were out of sight and mind throughout the whole process. Don’t let them erase us. Don’t let them walk with the tech that we helped invest in while we’re left holding the bag. #LMDX #LumiraDx #Roche #ElectraDx #ShareholderJustice #Fraud
1 · Reply
qwertylicious2003
qwertylicious2003 Jul. 28 at 3:16 PM
$RHHBY Trontinemab phase 3 announced shortly after closing ph2 enrollment. Very nice to see Roche move fast on progressing programs for early AD. $LCTX See guys - even though Trontinemab ph2 completion date shows 2031, its clear to see we could see ph2 close out enrollment and have a subsequent pivotal announcement very soon. With pivotal announcement comes $$$ in milestones and warrants. Big question is - do we get acquired prior to? Only time will tell!
3 · Reply
mrsBull
mrsBull Jul. 28 at 9:50 AM
$LMDX $RHHBY yes, yes, yes, yes and yes. I haven’t visited Lumira’s board for months now but I stand by my early opinion that the only chance shareholders had to see any kind of money was a lawsuit citing breach of duty. Lost a lot of money here, gain a valuable lesson (like with our friendly Chinese scam $MLGO ) Unless there’s a class action planned it’s time to move on guys
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 28 at 3:20 AM
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms $RHHBY https://stocktwits.com/news/equity/markets/roche-bets-big-on-alzheimer-s-prevention-with-new-trial-as-duchenne-drug-setback-looms/choeBswR5DR
0 · Reply
DonCorleone77
DonCorleone77 Jul. 28 at 3:02 AM
$RHHBY From Bloomberg: "Roche to Test Whether New Drug Can Prevent Alzheimer’s Disease" https://www.bloomberg.com/news/articles/2025-07-27/roche-to-test-whether-new-drug-can-prevent-alzheimer-s-disease?sref&
0 · Reply
Bulltrader988
Bulltrader988 Jul. 27 at 8:14 PM
$TPST there is a possible explanation for the run up last week and these rumours... $RHHBY so Roche failed in their product TIGIT https://www.oncologypipeline.com/apexonco/5000-patients-later-roche-scraps-its-tigit $TPST has possible solution.... $TPST 🤝🤝 $RHHBY already had a partnership together 👃👀
2 · Reply
Logic102
Logic102 Jul. 27 at 2:54 PM
$AVXL Prediction: 3-71 Schizophrenia 2b results will be excellent and make Anavex too expensive to fully Buy Out so we will see a deal in which Lilly $LLY or Roche $RHHBY is awarded a considerable portion of the company (over half for a controlling interest?). The recent Shelf line of credit will be crucial to finalizing this deal.
2 · Reply
Kylea1
Kylea1 Jul. 25 at 10:11 PM
$SRPT $RHHBY just buy this one out straight. It’s been battered enough.
0 · Reply
Kylea1
Kylea1 Jul. 25 at 9:44 PM
$SRPT ok. $RHHBY needs to take this one over for good.
0 · Reply
Leon_32
Leon_32 Jul. 25 at 6:25 PM
$TPST $RHHBY https://www.roche.com/venturefund/venturefund-portfolio Roche you can have my TPSTs Stocks for: 277$
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 25 at 2:32 PM
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback $SRPT $RHHBY https://stocktwits.com/news/equity/markets/sarepta-stock-down-after-eu-regulator-recommends-refusing-approval-to-its-contentious-gene-therapy/chob39GR5wO
0 · Reply
Optionking828
Optionking828 Jul. 25 at 1:27 PM
$ABBV $GMAB $JANX $JNJ $RHHBY still won’t matter - Janux is controlled by dark pool
0 · Reply
Quantumup
Quantumup Jul. 25 at 12:07 PM
Cantor reiterated $JANX Overweight-$200 and said, " $JANX unveiled 3 new early-stage pipeline programs after the close." $JNJ $RHHBY $ABBV $GMAB VIR CNTX MRK LVTX Cantor added, "In the context of the validation of its masked TCE platform from strong clinical data for JANX007 (PSMA x CD3 TCE), each of the programs resonates with us. They showcase both the versatility/modularity of the company's platform, as well as the company's creative ability to solve difficult biology challenges. Why now? Investor focus is obviously squarely on '007 so that these updates likely won't move the valuation needle much - but the company had committed to this R&D update at the start of the year. The company was emphatic that this pipeline update is coming from strength and confidence in '007 - and not meant to divert attention from it. With clinical trials expected to get underway over the next 1-4 quarters, this was seen as a prudent time to profile them."
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Jul. 25 at 11:03 AM
$SRPT EMA should have been pointed to the EMBARK part-2 results by $RHHBY .. as it clearly shows efficacy if treated for more than 12 month(!) I am sure they will do it - or supplied this data now. These treatments do take time.
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Jul. 25 at 10:56 AM
$SRPT oh - this application is for ambulatory patients, so $RHHBY can now supply info for more than 900 patients w/o death!
0 · Reply
LudwigVanBeethoven
LudwigVanBeethoven Jul. 25 at 10:54 AM
$SRPT FYI: Roche $RHHBY has 15 days to ask for re-examination (safety study, data, etc - Roche already made a positive restatement yesterday) https://www.ema.europa.eu/en/medicines/human/EPAR/elevidys
0 · Reply
DonCorleone77
DonCorleone77 Jul. 25 at 10:35 AM
$SRPT $RHHBY European Union committee recommends against Sarepta's Elevidys
3 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 25 at 8:34 AM
$FCN $LMDX $NDAQ $RHHBY This is not just mismanagement — it is fraud. It is a betrayal of trust, a corporate sleight of hand that left thousands of investors with nothing while insiders walked away with everything. #gates #truth #fraud #sec
1 · Reply